• Citer

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

par Strumberg, Dirk;Clark, Jeffrey W;Awada, Ahmad ;Moore, Malcolm J;Richly, Heike;Hendlisz, Alain ;Hirte, Hal W;Eder, Joseph P;Lenz, Heinz-Josef;Schwartz, Brian
Référence The oncologist, 12, 4, page (426-437)
Publication Publié, 2007-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Auteur:	Strumberg, Dirk; Clark, Jeffrey W; Awada, Ahmad; Moore, Malcolm J; Richly, Heike; Hendlisz, Alain; Hirte, Hal W; Eder, Joseph P; Lenz, Heinz-Josef; Schwartz, Brian
Informations sur la publication:	The oncologist, 12, 4, page (426-437)
Statut de publication:	Publié, 2007-04
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	BAY 43-9006
	Phase I clinical trials
	Review
	Sorafenib
MeSH keywords:	Antineoplastic Agents -- administration & dosage
	Antineoplastic Agents -- pharmacokinetics
	Antineoplastic Agents -- therapeutic use
	Benzenesulfonates -- administration & dosage
	Benzenesulfonates -- pharmacokinetics
	Benzenesulfonates -- therapeutic use
	Clinical Trials, Phase I as Topic
	Humans
	Neoplasm Metastasis
	Neoplasms -- drug therapy
	Neoplasms -- pathology
	Protein Kinase Inhibitors -- administration & dosage
	Protein Kinase Inhibitors -- pharmacokinetics
	Protein Kinase Inhibitors -- therapeutic use
	Pyridines -- administration & dosage
	Pyridines -- pharmacokinetics
	Pyridines -- therapeutic use
	raf Kinases -- antagonists & inhibitors
Note générale:	Journal Article
	Review
Langue:	Anglais
Identificateurs:	urn:issn:1083-7159
	info:doi/10.1634/theoncologist.12-4-426
	info:pii/12/4/426
	info:scp/34247857540
	info:pmid/17470685